PCM
VIR icon

Pathway Capital Management’s Vir Biotechnology VIR Stock Holding History

Pathway Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-472,552
Closed -$22.3M – 31
2021
Q2 		$22.3M Buy
472,552
+425,297
+900% +$19.3M 8.88% 3
2021
Q1 		$2.42M Buy
+47,255
New +$2.55M 13.43% 4

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pathway Capital Management's VIR Position: Q3 2021 in Review

Pathway Capital Management sold out of Vir Biotechnology (VIR) in Q3 2021, closing a stake of 472,552 shares — an estimated $22.3M sold.

Pathway Capital Management first reported a position in VIR in Q1 2021 and held it in 2 quarters. The position peaked at $22.3M in Q2 2021. 175 funds tracked by Wall St. Rank hold VIR as of Q3 2021.

  • Pathway Capital Management reported no remaining Vir Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Pathway Capital Management sold 472,552 Vir Biotechnology shares in Q3 2021, an estimated $22.3M.
  • Pathway Capital Management first reported a position in Vir Biotechnology in Q1 2021 and held it in 2 quarters.
  • Pathway Capital Management's Vir Biotechnology position peaked at $22.3M in Q2 2021.
  • 175 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2021.

Based on Pathway Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.